title: A combination of retinoic acid and proteasome inhibitors for the treatment of leukemias is potentially dangerous.
authors.forename: C
authors.initials: C
authors.lastname: Wójcik
authors.forename: I
authors.initials: I
authors.lastname: Mlynarczuk
authors.forename: G
authors.initials: G
authors.lastname: Hoser
authors.forename: J
authors.initials: J
authors.lastname: Kawiak
authors.forename: T
authors.initials: T
authors.lastname: Stoklosa
authors.forename: J
authors.initials: J
authors.lastname: Gołab
authors.forename: S
authors.initials: S
authors.lastname: Wilk
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016923:Cell Death / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003546:Cysteine Endopeptidases; D015853:Cysteine Proteinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology; D009097:Multienzyme Complexes; D046988:Proteasome Endopeptidase Complex; D014212:Tretinoin / Q000009:adverse effects* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D015853:Cysteine Proteinase Inhibitors; D009097:Multienzyme Complexes; D014212:Tretinoin; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex